Back to top

Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

In a report released yesterday, from Huafu Securities maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$297.44. The word on...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)